The U.S. Food and Drug Administration (FDA) has cleared imaging software developer Arterys' Oncology AI suite.
The software runs on Arterys' Medical Imaging Cloud AI (MICA) platform and helps clinicians measure and track tumors or potential cancers, according to the firm. Its initial deep-learning workflows are for liver MRI and CT scans and lung CT.
Going forward, Arterys plans to develop additional deep-learning tools for the software for solid tumors in other organs, the company said.
